{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:37:30Z","timestamp":1791286650387,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,8,2]],"date-time":"2009-08-02T00:00:00Z","timestamp":1249171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00280-009-1083-9","type":"journal-article","created":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T09:22:19Z","timestamp":1249118539000},"page":"765-773","source":"Crossref","is-referenced-by-count":175,"title":["Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma"],"prefix":"10.1007","volume":"65","author":[{"given":"Paul","family":"Haluska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Worden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schteingart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen N.","family":"Batzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Luisa","family":"Paccagnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gualberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,2]]},"reference":[{"issue":"9","key":"1083_CR1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJM199702273360907","volume":"336","author":"D Le Roith","year":"1997","unstructured":"Le Roith D (1997) Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336(9):633\u2013640","journal-title":"N Engl J Med"},{"issue":"5A","key":"1083_CR2","first-page":"3825","volume":"23","author":"MR Cardillo","year":"2003","unstructured":"Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F, Toscano V (2003) Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 23(5A):3825\u20133835","journal-title":"Anticancer Res"},{"issue":"12","key":"1083_CR3","first-page":"3796","volume":"8","author":"YS Chang","year":"2002","unstructured":"Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR et al (2002) Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8(12):3796\u20133802","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1083_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00384-004-0675-4","volume":"20","author":"R Durai","year":"2005","unstructured":"Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC (2005) The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 20(3):203\u2013220","journal-title":"Int J Colorectal Dis"},{"issue":"9113","key":"1083_CR5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","volume":"351","author":"SE Hankinson","year":"1998","unstructured":"Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B et al (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113):1393\u20131396","journal-title":"Lancet"},{"issue":"9","key":"1083_CR6","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1210\/en.2001-211408","volume":"143","author":"KR Kalli","year":"2002","unstructured":"Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA (2002) Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143(9):3259\u20133267","journal-title":"Endocrinology"},{"issue":"3","key":"1083_CR7","first-page":"627","volume":"63","author":"D Sachdev","year":"2003","unstructured":"Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D (2003) A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63(3):627\u2013635","journal-title":"Cancer Res"},{"issue":"3","key":"1083_CR8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1620\/tjem.209.217","volume":"209","author":"S Abe","year":"2006","unstructured":"Abe S, Funato T, Takahashi S, Yokoyama H, Yamamoto J, Tomiya Y et al (2006) Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 209(3):217\u2013228","journal-title":"Tohoku J Exp Med"},{"issue":"3","key":"1083_CR9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/0008-5472.CAN-06-2000","volume":"67","author":"GW Allen","year":"2007","unstructured":"Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL et al (2007) Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67(3):1155\u20131162","journal-title":"Cancer Res"},{"issue":"12","key":"1083_CR10","first-page":"BR521","volume":"8","author":"A Camirand","year":"2002","unstructured":"Camirand A, Lu Y, Pollak M (2002) Co-targeting HER2\/ErbB2 and insulin-like growth factor-1 receptors cause synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8(12):BR521\u2013BR526","journal-title":"Med Sci Monit"},{"issue":"11","key":"1083_CR11","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ijc.22221","volume":"119","author":"C Desbois-Mouthon","year":"2006","unstructured":"Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, Barbu V, Fartoux L, Poupon R et al (2006) Impact of IGF-1R\/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119(11):2557\u20132566","journal-title":"Int J Cancer"},{"issue":"suppl 1","key":"1083_CR12","first-page":"S99","volume":"12","author":"JM Gee","year":"2005","unstructured":"Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M et al (2005) Epidermal growth factor receptor\/HER2\/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(suppl 1):S99\u2013S111","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"1083_CR13","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/en.2005-0247","volume":"146","author":"JM Knowlden","year":"2005","unstructured":"Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI (2005) Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 146(11):4609\u20134618","journal-title":"Endocrinology"},{"issue":"5","key":"1083_CR14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.neo.7900242","volume":"4","author":"X Wan","year":"2002","unstructured":"Wan X, Helman LJ (2002) Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia 4(5):400\u2013408","journal-title":"Neoplasia"},{"issue":"16","key":"1083_CR15","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/0959-8049(93)90218-5","volume":"29A","author":"LR Wiseman","year":"1993","unstructured":"Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FE, Westley BR (1993) Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 29A(16):2256\u20132264","journal-title":"Eur J Cancer"},{"issue":"1","key":"1083_CR16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1179\/016164105X18151","volume":"27","author":"D Yin","year":"2005","unstructured":"Yin D, Tamaki N, Parent AD, Zhang JH (2005) Insulin-like growth factor-I decreased etoposide-induced apoptosis in glioma cells by increasing bcl-2 expression and decreasing CPP32 activity. Neurol Res 27(1):27\u201335","journal-title":"Neurol Res"},{"issue":"1","key":"1083_CR17","first-page":"1","volume":"1766","author":"RT Kurmasheva","year":"2006","unstructured":"Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766(1):1\u201322","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1083_CR18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/er.2006-0001","volume":"28","author":"AA Samani","year":"2007","unstructured":"Samani AA, Yakar S, Leroith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28(1):20\u201347","journal-title":"Endocr Rev"},{"issue":"7","key":"1083_CR19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","volume":"4","author":"MN Pollak","year":"2004","unstructured":"Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505\u2013518","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1083_CR20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","volume":"25","author":"P Icard","year":"2001","unstructured":"Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y et al (2001) Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 25(7):891\u2013897","journal-title":"World J Surg"},{"issue":"4","key":"1083_CR21","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W","volume":"88","author":"BL Wajchenberg","year":"2000","unstructured":"Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA et al (2000) Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88(4):711\u2013736","journal-title":"Cancer"},{"issue":"1","key":"1083_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jc.2005-1739","volume":"91","author":"LS Kirschner","year":"2006","unstructured":"Kirschner LS (2006) Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 91(1):14\u201321","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"1083_CR23","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356(23):2372\u20132380","journal-title":"N Engl J Med"},{"issue":"2","key":"1083_CR24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9440(10)63846-1","volume":"162","author":"TJ Giordano","year":"2003","unstructured":"Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL et al (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162(2):521\u2013531","journal-title":"Am J Pathol"},{"issue":"6","key":"1083_CR25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.surg.2005.09.031","volume":"138","author":"D Velazquez-Fernandez","year":"2005","unstructured":"Velazquez-Fernandez D, Laurell C, Geli J, Hoog A, Odeberg J, Kjellman M et al (2005) Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138(6):1087\u20131094","journal-title":"Surgery"},{"issue":"2","key":"1083_CR26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/0008-5472.CAN-06-3767","volume":"67","author":"AN West","year":"2007","unstructured":"West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, Pianovski MA et al (2007) Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67(2):600\u2013608","journal-title":"Cancer Res"},{"issue":"3","key":"1083_CR27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1530\/eje.0.1360296","volume":"136","author":"MM Weber","year":"1997","unstructured":"Weber MM, Auernhammer CJ, Kiess W, Engelhardt D (1997) Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 136(3):296\u2013303","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1083_CR28","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1158\/1078-0432.CCR-04-1070","volume":"11","author":"BD Cohen","year":"2005","unstructured":"Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE et al (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751, 871. Clin Cancer Res 11(5):2063\u20132073","journal-title":"Clin Cancer Res"},{"issue":"19","key":"1083_CR29","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","volume":"13","author":"P Haluska","year":"2007","unstructured":"Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR et al (2007) Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13(19):5834\u20135840","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1083_CR30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/jc.2008-1456","volume":"94","author":"FM Barlaskar","year":"2008","unstructured":"Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG et al (2008) Preclinical targeting of the type 1 insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94(1):204\u2013212","journal-title":"J Clin Endocrinol Metab"},{"key":"1083_CR31","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York (NY)","edition":"2"},{"issue":"19","key":"1083_CR32","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1200\/JCO.2007.15.9319","volume":"26","author":"MQ Lacy","year":"2008","unstructured":"Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D et al (2008) Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin-like growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26(19):3196\u20133203","journal-title":"J Clin Oncol"},{"issue":"8621","key":"1083_CR33","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0140-6736(88)90236-X","volume":"2","author":"Z Laron","year":"1988","unstructured":"Laron Z, Klinger B, Erster B, Anin S (1988) Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 2(8621):1170\u20131172","journal-title":"Lancet"},{"issue":"10","key":"1083_CR34","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1172\/JCI119438","volume":"99","author":"G Di Cola","year":"1997","unstructured":"Di Cola G, Cool MH, Accili D (1997) Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 99(10):2538\u20132544","journal-title":"J Clin Invest"},{"issue":"31","key":"1083_CR35","doi-asserted-by":"crossref","first-page":"23435","DOI":"10.1016\/S0021-9258(19)49481-7","volume":"268","author":"M Gronborg","year":"1993","unstructured":"Gronborg M, Wulff BS, Rasmussen JS, Kjeldsen T, Gammeltoft S (1993) Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase. J Biol Chem 268(31):23435\u201323440","journal-title":"J Biol Chem"},{"issue":"5","key":"1083_CR36","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1097-2765(00)80155-0","volume":"2","author":"JC Bruning","year":"1998","unstructured":"Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D et al (1998) A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2(5):559\u2013569","journal-title":"Mol Cell"},{"issue":"23","key":"1083_CR37","doi-asserted-by":"crossref","first-page":"16034","DOI":"10.1016\/S0021-9258(17)33969-8","volume":"269","author":"PY Chang","year":"1994","unstructured":"Chang PY, Benecke H, Le Marchand-Brustel Y, Lawitts J, Moller DE (1994) Expression of a dominant-negative mutant human insulin receptor in the muscle of transgenic mice. J Biol Chem 269(23):16034\u201316040","journal-title":"J Biol Chem"},{"issue":"15","key":"1083_CR38","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2008.19.9331","volume":"27","author":"DD Karp","year":"2009","unstructured":"Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F et al (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27(15):2516\u20132522","journal-title":"J Clin Oncol"},{"key":"1083_CR39","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/jco.2008.26.15_suppl.8000","volume":"26","author":"A Gualberto","year":"2008","unstructured":"Gualberto A, Melvin CL, Dean A, Ang AL, Reynolds JM, Lee AV et al (2008) Characterization of NSCLC patients responding to anti-IGF-IR therapy. J Clin Oncol 26:8000","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1083-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-1083-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1083-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T08:01:05Z","timestamp":1633766465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-1083-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,2]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["1083"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1083-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,2]]}}}